Caribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Andrew Guggenhime to its board of directors. Mr. Guggenhime is an accomplished biopharmaceutical industry leader with more than 20 years of experience. “Andrew brings a wealth of financial, strategic, and operational leadership experience...

Click to view original post